Acinetobacter baumannii has become a major cause of hospital-acquired infection worldwide. There are few papers regarding this particular subject. Our aim was to assess the incidence of bacteremia due to MDR Acinetobacter baumannii, factors associated with the infection, and clinical outcomes. We studied 49 cases of A. baumannii bacteremia in adult patients admitted to a university hospital in Northeast Thailand between 2005 and 2007. The incidence of MDR A. baumannii bacteremia was 3.6 episodes per 10,000 hospital admissions. Significantly independent factors associated with MDR A. baumannii bacteremia were previous: 1) ICU admission [odds ratio (OR) 10.01; 95% confidence interval (CI) 1.39-72.20]; 2) use of beta-lactam/beta-lactamase inhibitor antibiotics (OR 8.06; 95%CI 1.39-46.64); and 3) use of a carbapenem antibiotics (OR 11.40; 95%CI 1.44-89.98). The overall mortality rate was significantly higher in the MDR group than in the susceptible group (91.7% vs 48%, respectively) (p=0.001). The significantly independent factors related to mortality were: 1) APACHE II score (OR 1.25; 95%CI 1.03-1.52) and 2) secondary bacteremia (OR 14.86;). This study revealed the significantly independent factors associated with MDR A. baumannii bacteremia were prior ICU admission and prior use of broad spectrum antibiotics. This infection has a high mortality rate. Emphasis needs to be on prevention, strict application of infection control and appropriate use of antibiotics.
INTRODUCTION
Acinetobacter baumannii has emerged as a major cause of healthcare-associated infections worldwide and has recently been associated with hospital outbreaks (Villegas and Hartstein, 2003; Pimentel et al, 2005; Enoch et al, 2008; Peleg et al, 2008) . The alarming features of the organism are its development of resistance to all commercially available antibiotics and
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BACTEREMIA AT A UNIVERSITY HOSPITAL IN THAILAND Siriluck Anunnatsiri 1 and Pantipa Tonsawan its becoming a leading cause of death, especially among critically ill patients (Dijkshoorn et al, 2007; Perez et al, 2007; Gootz and Marra, 2008; Peleg et al, 2008) . Control of this organism is difficult because of its ability to survive for prolonged periods in the environment. A. baumannii can cause a wide range of nosocomial infections, among which the most frequent presentations are ventilator-associated pneumonia and bacteremia. The clinical manifestations of bacteremia range from transient bacteremia to fulminant septicemia, with a high crude mortality rate particularly associated with multidrug-resistant (MDR) strains.
Risk factors for infection with MDRAcinetobacter include prolonged hospitalization, admission to an intensive care unit (ICU), mechanical ventilation, colonization, exposure to broad spectrum antimicrobial agents, recent surgery, invasive procedures, and underlying severity of illness (Fournier and Richet, 2006; Playford et al, 2007) . Different sites of infection and geographic distribution may result in a difference in risk factors and outcomes; however, there have been few studies evaluating risk factors for MDRAcinetobacter bacteremia and its outcomes.
The purpose of the present study was to evaluate the incidence of MDR A. baumannii bacteremia and identify the risk factors for contracting this infection. The clinical outcomes and factors related to mortality among the patients were evaluated.
MATERIALS AND METHODS
A retrospective study was conducted among adult patients (over 15 years old), admitted between 2005 and 2007 at Srinagarind Hospital, a 1,000-bed, tertiary care, university hospital located in Northeast Thailand. Study patients were identified through the records of the clinical microbiological laboratory and data retrieved from their medical records. Patients were included if there was evidence of sepsis with at least one positive blood culture containing A. baumannii. For patients with more than one episode of A. baumannii bacteremia, only the first episode was considered. Patients with a positive blood culture containing multiple organisms including A. baumannii were excluded.
Information retrieved from medical records included: demographics, potential risk factors for developing MDR A. baumannii bacteremia, the clinical management, and the potential risk factors for death among the patients contracting A. baumannii bacteremia. The following data were recorded: age, sex, type of infection (community-acquired vs nosocomial infection following the definitions of the Centers for Diseases Control), admission ward at onset of A. baumannii bacteremia, co-morbid diseases/conditions, previous antibiotic therapy (receipt of a systemic antimicrobial agent for at least 24 hours during the three months preceding bacteremia), site of infection, drug susceptibility pattern, prescribed antimicrobial agents, clinical response to therapy, clinical outcome, and duration of hospitalization.
The severity of illness was estimated using the APACHE II score on the day of the positive blood culture (or within 24 hours). Also recorded were: 1) recent ICU stay, 2) prior surgery, 3) prior A. baumannii colonization, 4) prior bacteremia from other organisms, 5) treatment with cytotoxic drugs or corticosteroids (≥20 mg/day for >5 days) which occurred within 30 days of the onset of bacteremia, and 6) invasive procedures performed at least 48 hours to one week prior to the onset of bacteremia.
Definitions
MDR A. baumannii was defined as resistance to at least two b-lactam antimicrobials (including ceftazidime, cefotaxime, cefepime, cefpirome, ampicillin-sulbactam, piperacillin-tazobactam, cefoperazone-sulbactam), gentamicin or amikacin, ciprofloxacin or ofloxacin, and trimethoprim-sulfamethoxazole. Pandrug-resistant (PDR) A. baumannii was defined as: "resistance to all currently available antimicrobials except colistin or tigecycline by routine disk-diffusion method" (Falagas et al, 2006a) .
Empirical antimicrobial therapy was considered appropriate if the organism was susceptible in vitro to at least 1 of the drugs administered within 72 hours after the onset of bacteremia. Clinical outcomes were assessed 72 hours after the onset of bacteremia and defined as: 1) a complete response (ie, resolution of clinical sepsis); 2) a partial response (ie, improvement of clinical sepsis without complete resolution); and 3) failure (ie, absence of resolution, worsening of sepsis).
Blood cultures were processed using the BacT/Alert automated culture system (Organon Teknika, Durnham, NC) following the manufacturer's instructions. A. baumannii isolates were identified by standard microbiological techniques and antimicrobial susceptibility testing was determined by the disk diffusion technique, in accordance with Clinical and Laboratory Standards Institute criteria (NCCLS, 2000) . Intermediate susceptibility to antibiotics was considered as having resistance.
Ethical approval
The study protocol was approved by the Institutional Review Board of Khon Kaen University.
Statistical analysis
Data analysis was performed using 
RESULTS
During the 3-year period of the study, there were 84 episodes in 79 patients with positive blood cultures for A. baumannii, indicating an incidence of 7.8 cases per 10,000 hospital admissions. Among these, the incidences of MDR-and PDR-A. baumannii bacteremia were 3.6 and 1.8 cases per 10,000 hospital admissions, respectively. There was an increasing trend in antimicrobial resistance to several drugs during the 3-year study (Fig 1) .
Medical records were available for 65 cases (82.3%). Of these, 16 cases were excluded from the study due to contamination (6 cases), mixed infection (9 cases) and transfer to another hospital (1 case). Among the remaining 49 cases, 25 (51%) and 24 cases (49%), respectively, had non-MDR and MDR A. baumannii bacteremia and 15 of the 24 MDR A. baumannii cases (62.5%) had PDR A. baumannii infection.
The demographic data are presented in Missing data = patients received an antibiotic for which the susceptibility pattern was not known.
The proportions of patients who received appropriate empirical antimicrobial therapy and appropriate antimicrobial therapy during the course of bacteremia were significantly lower in patients with MDR A. baumannii bacteremia (25% vs 95.5%, p<0.001; 41.7% vs 95.8%, p<0.001; respectively) ( Table 2 ). The median (range) duration from the onset of bacteremia to receipt of appropriate antimicrobial therapy was significantly longer in patients with MDR A. baumannii bacteremia [2.5 (0-5) vs 0 (0-9) days, p=0.006]. Seventy-two hours after the onset of bacteremia, there was a significantly lower proportion of patients who survived with MDR A. baumannii bacteremia (41.7% vs 76%, p=0.02). Of the 29 patients surviving at 72 hours; there was a significantly greater proportion with worse outcomes among patients with MDR A. baumannii bacteremia (p=0.02). The overall mortality rate was significantly higher in patients with MDR A. baumannii bacteremia (22 cases; 91.7% vs 12 cases; 48%, p=0.001).
On univariate analysis, the factors significantly related to mortality in patients with A. baumannii bacteremia were: 1) higher APACHE II score, 2) older age, 3) secondary bacteremia, 4) having pneumonia, and 5) MDR A. baumannii infection (Table 3) . On multivariate analysis, two factors were related to mortality: a higher APACHE II score (OR 1.25; 95%CI 1.03-1.52) and secondary bacteremia (OR 14.86; 95%CI 1.37-161.90).
DISCUSSION
MDR A. baumannii has become a serious nosocomial pathogen causing a variety of clinical manifestations. Nosocomial septicemia is one of the most important problems facing modern medicine. Patients with MDR A. baumannii bacteremia have higher mortality and medical costs than non-MDR A. baumannii bacteremia patients. These bacteria must be identified quickly in order to adjust empirical treatment (Lee et al, 2007; Sunenshine et al, 2007) . In a case-control study, Shih et al (2008) found four independent risk factors associated with multidrug resistance in A. baumannii septicemia: previous colonization with A. baumannii, antecedent antimicrobial therapy, the number of prescribed antibiotics, and a recent invasive procedure. In contrast to the present study, they did not identify the effect of different classes of antibiotics on the development of MDR-A. baumannii septicemia. The present study showed exposure to broad spectrum antibiotics, such as carbapenem or beta-lactam/beta-lactamase inhibitor antimicrobials was independently related to MDR-A. baumannii bacteremia.
Our findings are similar to a metaanalysis done on the association between exposure to broad spectrum antibiotics and the development of MDR-A. baumannii infection (Falagas and Kopterides, 2006b ). Exposure to these antibiotics results in the emergence of resistance due to selective pressure and interruption of the colonization resistance mechanism. Previous colonization with A. baumannii was not an independent risk factor in the present study but prior ICU stay was. Using passively collected culture data may underestimate the significance of colonization in our study. Conditions in the ICU provide an environment conducive to the development and maintenance of MDR-A. baumannii. Most patients admitted to the ICU are severely ill, need interventions and frequently receive antibiotics, all of which promote multidrug resistant colonization and subsequent infection in susceptible patients. The present study may have underestimated the significance of bacterial colonization because of limited surveillance culture data.
Therapeutic options are limited for MDR-A. baumannii infection, especially if the isolates are resistant to carbapenem class antibiotics, of which polymyxin or tigecycline may be the only ones available for treatment (Maragakis and Perl, 2008 Compared to previous studies (Kuo et al, 2007; Lee et al, 2007) , the overall mortality rate for A. baumannii bacteremia at our hospital was high: 48% in non-MDR A. baumannii infection and > 90% in MDR-A. baumannii. During the study period, polymyxin and tigecycline were not available at our hospital, which led to a high proportion of patients with MDR-A. baumannii bacteremia not receiving appropriate antimicrobial therapy resulting in a significantly higher mortality rate than expected. Previous studies have found the administration of ineffective antimicrobial therapy for carbapenem-resistant A. baumannii bacteremia is a predictor of mortality (Kwon et al, 2007; Jamulitrat et al, 2009 ). The present study supports the association between inappropriate antimicrobial treatment and increasing mortality among patients. Awareness by the physician of risk factors for MDR-A. baumannii infection, available effective antimicrobial agents, and intensive care support may improve clinical outcomes among these patients.
Although MDR-A. baumannii bacteremia is associated with mortality in the present study as demonstrated on univariate analysis; it was not a major determinant of mortality. The present study showed the independent factors related to death among patients with A. baumannii bacteremia were severity of illness and secondary bacteremia. On multivariate analysis assessing the risk factors for mortality showed increasing trend in mortality in patients contracting MDR-A. baumannii bacteremia, albeit not statistically significant (OR 10.243; ) possibly due to small sample size. The higher mortality rate in patients with MDR-A. baumannii bacteremia may not be directly attributable to drug resistance but may be confounded by the effects of underlying disease severity, inappropriate antibiotic treatment and primary source of infection (Jamulitrat et al, 2009) . Approximately 40% of patients in the present study had pneumonia as a primary source of A. baumannii bacteremia, which is nearly 2 times more common in MDR than in the non-MDR group. Our results support the findings of Agbaht et al (2007) that the bacteremic ventilator-associated pneumonia is more often caused by multidrug-resistant organisms with a higher risk of death.
The present study had limitations. Based on the retrospective study design, some missing data could have resulted in selection bias. Moreover, the small sample size may have affected the power of the study to detect differences. The study design, which used cases with non-MDR-A. baumannii bacteremia as the comparable group, may have overestimated the significance of antibiotics as a risk factor for contracting MDR-A. baumannii bacteremia (Harris et al, 2002) .
In conclusion, this study revealed the significant independent factors associated with MDR A. baumannii bacteremia were previous ICU admission and prior use of broad spectrum antibiotics. This infection is associated with a high mortality rate, especially in patients not receiving appropriate treatment. Emphasis needs to be placed on prevention, strict application of infection control, and appropriate use of antibiotics, all of which might reduce the risk and improve the control of this infection.
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